**SUMMARY SHEET**

<table>
<thead>
<tr>
<th>AGENDA NR.  1.12 – 11.0</th>
<th><strong>STOP TB PARTNERSHIP INITIATIVES GDF</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IS THIS SESSION FOR:</strong></td>
<td>INFORMATION □  DISCUSSION ☑  DECISION ☑</td>
</tr>
</tbody>
</table>

**BACKGROUND (INCLUDING PROBLEM STATEMENT):**
The Global Drug Facility was established in 2001 as a mechanism to ensure uninterrupted supply of anti-TB drugs. In 2010, an external review was conducted by the Boston Consulting Group on the strategic direction for GDF moving into its second decade of operations. The GDF Implementation and Restructuring Plan was adopted by the CB at the October 2010 meeting. At the March 2011 CB, the new GDF manager presented her assessment of the BCG evaluation and proposed a revised organigram and one procurement option for discussion and decision by the CB. During the Q3 and Q4 additional new options for procurement for GDF were presented and discussed by the GDF manager, senior staff in GDF, Executive Secretary and WHO. It became clear that a decision on the way in which GDF will deliver over most of its function, mainly procurement, can not be taken without the involvement and guidance of the Coordinating Board.

Based on a call with the Executive Committee, an independent consultancy was commissioned in order to review the expectations and to determine the best structure for the future of TB drug supply.

This session will have 2 presentations separated by discussions:
- one presentation provides key achievements and challenges of GDF operations, reforms and deliverables in 2011
- one presentation will propose various options and implications for future of TB drug supply

**SUMMARY/OUTLINE OF THE SESSION:**

Presentation 1 will cover the following areas of GDF work:
- GDF procurement and country support comparisons 2010/2011
- Performance and order management improvements
- Market development activities
- Organization and governance
- 2012 plans for country support and review of GDF expert committees and grant policy

Presentation 2 will cover the following areas:
- Overview of where the GDF is now and how it got here.
- Exposition of the performance, strengths and weaknesses of the current operation.
- Comparison of the risks and benefits from choosing different operational structures

The presentations will take 15 - 20 minutes each.

**MAJOR DISCUSSION POINTS OR DECISION POINTS REQUESTED:**
1. Discuss and acknowledgement of the work and achievements of GDF in 2011
2. Based on the various options presented, the CB will recommend to the Secretariat, Executive Secretary and GDF a clear way forward for a Changed GDF
3. Discuss and decide to strengthen the Business Advisory Committee (BAC) with some CB members and alternates as an advisory body for the Coordinating Board, Executive Secretary and Stop TB Partnership Secretariat - on GDF related matters and operations.

_If so, what funding is already available?_

---

**21st Stop TB Partnership Coordinating Board Meeting**
30 January – 1 February 2012 - Bangkok, Thailand
What is the funding gap?

Are there HR implications? Yes ☒ No ☐. If so, what? HR implications depend on the procurement option decided upon by the CB. Different options require different numbers and levels of staff. Some options require an increase in numbers of staff, most options require some decrease.

**Next Steps**

**ACTION REQUIRED:** Next steps depend on the procurement option decided upon by the CB.

**RESPONSIBLE AGENCY/OFFICER:** GDF Manager and Executive Secretary

**TIMEFRAME:** Within six months.